CSBio CSBio

X
[{"orgOrder":0,"company":"NewAmsterdam Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NewAmsterdam Pharma Doses First Patient in Phase 3 BROADWAY Trial of Obicetrapib in Adults with Heterozygous Familial Hypercholesterolemia and\/or Established Atherosclerotic Cardiovascular Disease","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"NETHERLANDS","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"NewAmsterdam Pharma"},{"orgOrder":0,"company":"NewAmsterdam Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Review Article in ESC\u2019s Cardiovascular Research Examines Cholesteryl Ester Transfer Protein (CETP) Inhibition\u2019s Role in Reducing Cardiovascular Disease Risk","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"NETHERLANDS","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"NewAmsterdam Pharma"},{"orgOrder":0,"company":"NewAmsterdam Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NewAmsterdam Pharma Doses First Patient in PREVAIL, the Cardiovascular Outcomes Trial of Obicetrapib in Adults with Atherosclerotic Cardiovascular Disease (ASCVD)","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"NETHERLANDS","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"NewAmsterdam Pharma"},{"orgOrder":0,"company":"NewAmsterdam Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NewAmsterdam Pharma to Present at Upcoming Medical Conferences New Post-Hoc Analyses from Phase 2 ROSE Trial of Obicetrapib in Patients with Dyslipidemia","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"NETHERLANDS","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"NewAmsterdam Pharma"},{"orgOrder":0,"company":"NewAmsterdam Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NewAmsterdam Pharma Shares New Data from Phase 2b ROSE Study Showing up to 82.5% of Patients with Dyslipidemia Attained LDL-c Goals","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"NETHERLANDS","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"NewAmsterdam Pharma"},{"orgOrder":0,"company":"NewAmsterdam Pharma","sponsor":"Frazier Lifesciences Acquisition Corporation","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"NewAmsterdam Pharma Holding B.V. and Frazier Lifesciences Acquisition Corporation Announce Merger Agreement to Create Publicly Listed Company Focused on Transformative Oral Therapies for Major Cardiometabolic Diseases","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"NETHERLANDS","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"NewAmsterdam Pharma"},{"orgOrder":0,"company":"NewAmsterdam Pharma","sponsor":"Frazier Healthcare Partners","pharmaFlowCategory":"D","amount":"$235.0 million","upfrontCash":"Undisclosed","newsHeadline":"NewAmsterdam Pharma Holding B.V. and Frazier Lifesciences Acquisition Corporation Announce Merger Agreement to Create Publicly Listed Company Focused on Transformative Oral Therapies for Major Cardiometabolic Diseases","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"NETHERLANDS","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"NewAmsterdam Pharma"},{"orgOrder":0,"company":"NewAmsterdam Pharma","sponsor":"Frazier Healthcare Partners","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NewAmsterdam Pharma Announces Publication in Nature Medicine Discussing Clinical Potential of Obicetrapib","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"NETHERLANDS","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"NewAmsterdam Pharma"},{"orgOrder":0,"company":"NewAmsterdam Pharma","sponsor":"Frazier Healthcare Partners","pharmaFlowCategory":"D","amount":"$235.0 million","upfrontCash":"Undisclosed","newsHeadline":"NewAmsterdam Pharma Debuts as Publicly Traded Company Focused on Developing Obicetrapib, a Low-Dose, Once-Daily Oral LDL-Lowering Agent with Promising Safety and Efficacy Clinical Data, as a Potential Preferred Therapy for High Risk Cardiovascular Disease","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"NETHERLANDS","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"NewAmsterdam Pharma"},{"orgOrder":0,"company":"NewAmsterdam Pharma","sponsor":"Menarini","pharmaFlowCategory":"D","amount":"$1,061.5 million","upfrontCash":"$121.0 million","newsHeadline":"NewAmsterdam Pharma and The Menarini Group Sign Licensing Deal to Commercialize Obicetrapib in Europe","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"NETHERLANDS","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"NewAmsterdam Pharma"},{"orgOrder":0,"company":"NewAmsterdam Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NewAmsterdam Pharma Announces Positive Topline Results from Phase 2b Dose-Finding Trial Evaluating Obicetrapib in Japanese Patients","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"NETHERLANDS","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"NewAmsterdam Pharma"},{"orgOrder":0,"company":"NewAmsterdam Pharma","sponsor":"Jefferies","pharmaFlowCategory":"D","amount":"$173.5 million","upfrontCash":"Undisclosed","newsHeadline":"NewAmsterdam Pharma Announces Pricing of $175.3 Million Public Offering of Ordinary Shares and Pre-Funded Warrants","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"NETHERLANDS","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2024","url1":"","url2":"","graph1":"Small molecule","graph2":"NewAmsterdam Pharma"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...
Filters Filter
×
FILTER:
filter News Type
    filter Company
      filter Product Type
        filter Deal Size
          filter Upfront Payment

            Active Filter(s):

            Product Type

            Companies

            Details:

            The net proceeds will be used for the development of TA-8995 (obicetrapib). It is a selective cholesteryl ester transfer protein inhibitor that potently decreases (LDL-C) as well as increases (HDL-C), which is used for the treatment of atherosclerotic Cardiovascular disease.

            Lead Product(s): Obicetrapib

            Therapeutic Area: Cardiology/Vascular Diseases Product Name: TA-8995

            Highest Development Status: Phase III Product Type: Small molecule

            Partner/Sponsor/Collaborator: Jefferies

            Deal Size: $173.5 million Upfront Cash: Undisclosed

            Deal Type: Public Offering February 13, 2024

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            TA-8995 (obicetrapib) is a next-generation, non statin, oral once-daily, low-dose CETP inhibitor having the potential for lowering LDL-C. It is currently being investigated in combination with ezetimibe as an adjunct to high-intensity statin therapy.

            Lead Product(s): Obicetrapib

            Therapeutic Area: Cardiology/Vascular Diseases Product Name: TA-8995

            Highest Development Status: Phase III Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable June 05, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Proceeds from this transaction will be used for three ongoing phase 3 trials, BROADWAY, BROOKLYN and PREVAIL, evaluating the effect of TA-8995 (obicetrapib) in patients with atherosclerotic cardiovascular disease and heterozygous familial hypercholesterolemia.

            Lead Product(s): Obicetrapib

            Therapeutic Area: Cardiology/Vascular Diseases Product Name: TA-8995

            Highest Development Status: Phase III Product Type: Small molecule

            Partner/Sponsor/Collaborator: Frazier Healthcare Partners

            Deal Size: $235.0 million Upfront Cash: Undisclosed

            Deal Type: Private Placement November 23, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Treatment with TA-8995 (obicetrapib) in patients on high-intensity statin therapy was observed to have statistically significant impact on LDL-C, as well as significant impacts on ApoB, non-HDL-C, HDL-C and Lp(a), additional key measures of cardiovascular disease risk.

            Lead Product(s): Obicetrapib,Atorvastatin

            Therapeutic Area: Cardiology/Vascular Diseases Product Name: TA-8995

            Highest Development Status: Phase III Product Type: Small molecule

            Partner/Sponsor/Collaborator: Frazier Healthcare Partners

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable August 11, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            NewAmsterdam is investigating TA-8995 (obicetrapib), a next-generation oral, low-dose and once-daily CETP inhibitor, as the preferred LDL-C-lowering therapy for high-risk cardiovascular disease (“CVD”) patients.

            Lead Product(s): Obicetrapib

            Therapeutic Area: Cardiology/Vascular Diseases Product Name: TA-8995

            Highest Development Status: Phase III Product Type: Small molecule

            Partner/Sponsor/Collaborator: Frazier Lifesciences Acquisition Corporation

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Merger July 25, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            NewAmsterdam is investigating TA-8995 (obicetrapib), a next-generation oral, low-dose and once-daily CETP inhibitor, as the preferred LDL-C-lowering therapy for high-risk cardiovascular disease (“CVD”) patients.

            Lead Product(s): Obicetrapib

            Therapeutic Area: Cardiology/Vascular Diseases Product Name: TA-8995

            Highest Development Status: Phase III Product Type: Small molecule

            Partner/Sponsor/Collaborator: Frazier Healthcare Partners

            Deal Size: $235.0 million Upfront Cash: Undisclosed

            Deal Type: Financing July 25, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Under the collaboration agreement, NewAmsterdam will retain all rights to commercialize obicetrapib in cardiovascular diseases, if approved, in the rest of the world, as well as rights to develop certain forms of TA-8995 for other diseases such as Alzheimer's disease.

            Lead Product(s): Obicetrapib

            Therapeutic Area: Cardiology/Vascular Diseases Product Name: TA-8995

            Highest Development Status: Phase III Product Type: Small molecule

            Partner/Sponsor/Collaborator: Menarini

            Deal Size: $1,061.5 million Upfront Cash: $121.0 million

            Deal Type: Licensing Agreement June 28, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            TA-8995 (Obicetrapib) is a next-generation oral, low-dose and once-daily CETP inhibitor in development for lowering low-density lipoprotein cholesterol (LDL-c) and preventing major adverse cardiovascular events.

            Lead Product(s): Obicetrapib

            Therapeutic Area: Cardiology/Vascular Diseases Product Name: TA-8995

            Highest Development Status: Phase III Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable June 06, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            TA-8995 (obicetrapib) is next-generation CETP inhibitor, initially in development for patients at high risk for cardiovascular disease as an adjunct to maximally tolerated statin therapy, both as a monotherapy and in a fixed-dose combination with ezetimibe.

            Lead Product(s): Obicetrapib

            Therapeutic Area: Cardiology/Vascular Diseases Product Name: TA-8995

            Highest Development Status: Phase III Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable May 19, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            PREVAIL evaluates whether obicetrapib, a novel cholesteryl ester transfer protein inhibitor, lowers the risk of adverse cardiovascular outcomes in individuals with ASCVD, who are not adequately controlled despite maximally tolerated lipid-modifying therapies.

            Lead Product(s): Obicetrapib

            Therapeutic Area: Cardiology/Vascular Diseases Product Name: TA-8995

            Highest Development Status: Phase III Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable March 01, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY